Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...
Understanding the mechanisms of resistance to cancer treatments is necessary to find effective therapies at different stages of the disease. Scientists at UT Southwestern Medical Center studied the ...
Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...
A real-world cohort of patients with metastatic pancreatic adenocarcinoma (mPDAC) demonstrated that prophylaxis therapy to alleviate toxic effects was ...
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...
The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic ...
Managing weight loss with telotristat ethyl in patients with metastatic pancreatic ductal adenocarcinoma may improve survival ...
High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...
Medical announced positive interim data from multiple clinical trials, including safety and feasibility studies treating ...
Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.
Press Release ImmunoMet Therapeutics, Inc., ("ImmunoMet", or the "Company"), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today provided a data ...